Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2021

Yasuda Hiroyuki, Ichihara Eiki, Sakakibara-Konishi Jun, Zenke Yoshitaka, Takeuchi Shinji, Morise Masahiro, Hotta Katsuyuki, Sato Mineyoshi, Matsumoto Shingo, Tanimoto Azusa, Matsuzawa Reiko, Kiura Katuyuki, Takashima Yuta, Yano Seiji, Koyama Junji, Fukushima Takahiro, Hamamoto Junko, Terai Hideki, Ikemura Shinnosuke, Takemura Ryo, Goto Koichi, Soejima Kenzo

Abstract excerpt

OBJECTIVES: Several preclinical data proposed a potential efficacy of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins)-positive non-small cell lung cancer (NSCLC). However, reported case series and a retrospective study proposed controversial efficacy. The efficacy of osimertinib in EGFR ex20ins-positive NSCLC have not been well evaluated in prospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutagenesis, Insertional

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 34808485
DOI: 10.1016/j.lungcan.2021.10.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.PMID 34808485Read ↗

Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.Semantic proximity Read ↗

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.Semantic proximity Read ↗

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.Semantic proximity Read ↗

A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19).Semantic proximity Read ↗

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancerSemantic proximity Read ↗

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancerSemantic proximity Read ↗

Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.Semantic proximity Read ↗

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.Semantic proximity Read ↗

A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.Semantic proximity Read ↗

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidationSemantic proximity Read ↗

EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read ↗

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.